article · Applied Sciences
A newly synthesised non-symmetric bis-isatin derivative, known as compound 3, has shown notable anti-proliferative activity against cancer cells. To understand how the potential therapeutic travels in the body, laboratory tests examined its interaction with bovine serum albumin, a key drug-carrier protein. Spectroscopic evaluations demonstrated that compound 3 binds effectively with albumin to form a stable, non-fluorescent complex via static quenching, without altering the protein's overall shape. Thermodynamic analysis confirmed that this binding is spontaneous, driven by hydrogen bonding and electrostatic attractions. Competitive binding experiments and molecular docking models further showed that compound 3 occupies Sudlow site I on the protein, directly competing with warfarin with a calculated binding energy of minus 25.93 kilojoules per mole. These findings detail the transport and protein-binding mechanics of a promising anti-proliferative agent.
Understanding how prospective drug candidates interact with major blood proteins is essential for predicting their distribution, lifespan, and safety in the body. By defining how compound 3 binds to serum albumin without distorting protein structure, this research provides vital baseline biophysical data needed to evaluate whether the molecule can effectively travel through the circulatory system during cancer treatment.
This research sits at an early, laboratory-based discovery stage. The findings are primarily relevant to pharmaceutical researchers and medicinal chemists working on small-molecule cancer therapeutics and drug-delivery profiling. Real-world application depends on further preclinical testing, formulation development, and in vivo pharmacology to determine whether the compound can progress into a viable anti-cancer drug candidate.
AI-generated from the published abstract. Always read the original work before citing.
As part of the research endeavors to combat cancer, a non-symmetric bis-isatin derivative (compound 3) was synthesized and showed a significant anti-proliferative potency. The current study provides a comprehensive characterization of the interaction of compound 3 with the drug-transporting protein bovine serum albumin (BSA) via the use of spectroscopic tools along with molecular docking studies. Fluorescence spectral measurements showed that the BSA intrinsic fluorescence can be significantly quenched by the addition of compound 3 and the formation of a non-fluorescent complex. Further measurements revealed a static type of quenching with Stern–Volmer and Linweaver–Burk constants of 105. The thermodynamic parameters of the binding were calculated to be ΔS° 105.09 ± 5.32 with ΔH° of −0.72 ± 0.71 and negative ΔG° values. In addition, synchronous fluorescence and 3D fluorescence spectroscopy suggested that compound 3 did not induce conformational changes in BSA. Site competition experiments revealed that compound 3 competes with warfarin within the BSA binding domain (Sudlow site I). This was further confirmed by the molecular docking results showing a binding energy of −25.93 kJ/mol for compound 3-BSA. Hence, the observed results in the present study assumed that the compound 3-BSA binding is spontaneous, involving electrostatic forces and hydrogen bonding.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/app7060617
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
